Stay updated on Switching to Cabotegravir and Rilpivirine: Clinical Trial
Sign up to get notified when there's something new on the Switching to Cabotegravir and Rilpivirine: Clinical Trial page.

Latest updates to the Switching to Cabotegravir and Rilpivirine: Clinical Trial page
- Check5 days agoChange DetectedThe page now displays the clinical trial record, including study details, results measures, eligibility criteria, locations, and supporting documents, rather than a 403 error page.SummaryDifference100%

- Check11 days agoChange DetectedThe footer revision changes from v3.7.2 to v3.8.0 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check18 days agoChange DetectedA site-wide banner announces that NIH is transitioning to the term “Super Intelligence” in place of “Artificial Intelligence” and links to updates and FAQs.SummaryDifference1%

- Check25 days agoChange DetectedThe footer revision identifier changes from v3.7.1 to v3.7.2 on the ClinicalTrials.gov error page.SummaryDifference0.2%

- Check32 days agoChange DetectedThe footer's site revision identifier updates from v3.7.0 to v3.7.1. The page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check53 days agoChange Detected403 Forbidden error header now appears on the page, with a Home link and a Revision: v3.7.0 notice, replacing the previous study content and signaling that the page is inaccessible.SummaryDifference21%

Stay in the know with updates to Switching to Cabotegravir and Rilpivirine: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Switching to Cabotegravir and Rilpivirine: Clinical Trial page.